| Title |
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
|
|---|---|
| Published in |
Clinical and Translational Medicine, December 2015
|
| DOI | 10.1186/s40169-015-0075-0 |
| Pubmed ID | |
| Authors |
Saveri Bhattacharya, Mark A. Socinski, Timothy F. Burns |
| Abstract |
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS-RAF-MEK-ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted. |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Unknown | 72 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 19% |
| Researcher | 12 | 16% |
| Student > Ph. D. Student | 10 | 14% |
| Student > Master | 7 | 10% |
| Student > Postgraduate | 6 | 8% |
| Other | 13 | 18% |
| Unknown | 11 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 22 | 30% |
| Medicine and Dentistry | 13 | 18% |
| Agricultural and Biological Sciences | 12 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Unspecified | 3 | 4% |
| Other | 3 | 4% |
| Unknown | 13 | 18% |